https://assets.capyfin.com/instruments/678fdc13234e27009c5d6080.png avatar
Beauty Health
🇺🇸 NASDAQ:SKIN
View Company
OverviewEarningsDividends
•
Dec 31, 2022

Beauty Health Q4 2022 Earnings Report

Reported a strong fourth quarter, exceeding expectations and achieving significant year-over-year growth.

Key Takeaways

BeautyHealth reported a strong Q4 2022, with net sales increasing by 26% year-over-year to $98.1 million and net income reaching $3.8 million. Adjusted EBITDA also saw a substantial increase of 92% to $16.3 million. The company's performance was driven by growth in both delivery systems and consumables, with notable contributions from the Americas and APAC regions.

Net sales increased by 26% to $98.1 million compared to Q4 2021.

Delivery Systems net sales increased +19% to $50.7 million.

Consumables net sales increased +35% to $47.4 million compared to Q4 2021.

Adjusted EBITDA increased +92% to $16.3 million compared to Q4 2021.

Total Revenue
$98.1M
Previous year: $77.9M
+26.0%
EPS
$0.05
Previous year: -$0.12
-141.7%
Gross Margin
66.4%
Previous year: 72.9%
-8.9%
Adjusted EBITDA Margin
16.6%
Previous year: 10.9%
+52.3%
Adjusted Gross Margin
72.3%
Previous year: 76.5%
-5.5%
Gross Profit
$65.2M
Previous year: $56.8M
+14.9%
Cash and Equivalents
$568M
Previous year: $902M
-37.0%
Free Cash Flow
-$6.36M
Previous year: -$3.07M
+107.5%
Total Assets
$1.01B
Previous year: $1.22B
-17.2%

Beauty Health

Beauty Health

Beauty Health Revenue by Segment

Beauty Health Revenue by Geographic Location

Forward Guidance

BeautyHealth expects net sales in the range of $450 to $470 million for fiscal 2023 and reiterates its outlook for fiscal 2023 adjusted EBITDA margin of 18% to 20% and its fiscal 2025 long-range outlook of $600 million to $700 million net sales and 25% to 30% adjusted EBITDA margin.

Positive Outlook

  • Net sales in the range of $450 to $470 million for fiscal 2023
  • Fiscal 2023 adjusted EBITDA margin of 18% to 20%
  • Fiscal 2025 long-range outlook of $600 million to $700 million net sales
  • Fiscal 2025 adjusted EBITDA margin of 25% to 30%
  • Fiscal 2023 gross margin to exceed fiscal 2022 gross margin

Challenges Ahead

  • Potential risk for further market closures or other restrictive measures from existing or new COVID-19 strains
  • Uneven global rollout and adoption of vaccines
  • Inflationary headwinds related to higher raw material, shipping and labor costs
  • Assumes no material deterioration in general market conditions or other unforeseen circumstances beyond our control
  • Does not take into account the impact of any unanticipated developments in the business or changes in the operating environment, nor does it take into account any acquisitions, dispositions or financings during 2023

Revenue & Expenses

Visualization of income flow from segment revenue to net income

Company Overview

Full financial data and analysis

View Beauty Health